$10.19
1.55% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US69913P1057
Symbol
FNA
Sector

Paragon 28 Stock price

$10.19
+0.20 2.00% 1M
+3.54 53.23% 6M
-2.24 18.02% YTD
-2.50 19.70% 1Y
-6.50 38.95% 3Y
-8.52 45.54% 5Y
-8.52 45.54% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.16 1.55%
ISIN
US69913P1057
Symbol
FNA
Sector

Key metrics

Market capitalization $853.11m
Enterprise Value $924.58m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.77
P/S ratio (TTM) P/S ratio 3.48
P/B ratio (TTM) P/B ratio 6.11
Revenue growth (TTM) Revenue growth 18.16%
Revenue (TTM) Revenue $245.00m
EBIT (operating result TTM) EBIT $-53.93m
Free Cash Flow (TTM) Free Cash Flow $-58.20m
Cash position $39.15m
EPS (TTM) EPS $-0.88
P/E forward negative
P/S forward 3.36
EV/Sales forward 3.64
Short interest 7.57%
Show more

Is Paragon 28 a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Paragon 28 Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Paragon 28 forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Paragon 28 forecast:

Buy
100%

Financial data from Paragon 28

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
245 245
18% 18%
100%
- Direct Costs 88 88
67% 67%
36%
157 157
2% 2%
64%
- Selling and Administrative Expenses 164 164
12% 12%
67%
- Research and Development Expense 28 28
0% 0%
12%
-35 -35
73% 73%
-14%
- Depreciation and Amortization 19 19
26% 26%
8%
EBIT (Operating Income) EBIT -54 -54
54% 54%
-22%
Net Profit -73 -73
9% 9%
-30%

In millions USD.

Don't miss a Thing! We will send you all news about Paragon 28 directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Paragon 28 Stock News

Neutral
Business Wire
18 days ago
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), (the “Company”) a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demsk...
Neutral
PRNewsWire
30 days ago
NEW YORK , Nov. 29, 2024 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Paragon 28, Inc. (NYSE: FNA) between May 5, 2023 and September 20, 2024, both dates inclusive (the "Class Period"), and those who purchased Paragon 28 call options or sold put options during the Class Period, of the November 29, 2024 lead plaintiff deadline in ...
Neutral
GlobeNewsWire
about one month ago
Investors can contact the law firm at no cost to learn more about recovering their losses
More Paragon 28 News

Company Profile

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.

Head office United States
CEO Albert DaCosta
Employees 574
Founded 2010
Website www.paragon28.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today